Display options
Cite
Zhu H, Lo HW. The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Curr Genomics. 2010;11(4):238-45doi: 10.2174/138920210791233108.
Zhu, H., & Lo, H. W. (2010). The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Current genomics, 11(4), 238-45. https://doi.org/10.2174/138920210791233108
Zhu, Hu, and Lo, Hui-Wen. "The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases." Current genomics vol. 11,4 (2010): 238-45. doi: https://doi.org/10.2174/138920210791233108
Zhu H, Lo HW. The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Curr Genomics. 2010 Jun;11(4):238-45. doi: 10.2174/138920210791233108. PMID: 21119888; PMCID: PMC2930663.
Copy Download .nbib Format: NLM
Share it on

Curr Genomics. 2010 Jun;11(4):238-45. doi: 10.2174/138920210791233108.

The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases.

Current genomics

Hu Zhu, Hui-Wen Lo

Affiliations

  1. Department of Surgery, Division of Surgical Sciences, Duke University School of Medicine.

PMID: 21119888 PMCID: PMC2930663 DOI: 10.2174/138920210791233108

Abstract

Sonic hedgehog (Shh) signaling is critically important for embryogenesis and other cellular processes in which GLI transcription factors mediate the terminal effects of the pathway. GLI1, in particular, plays a significant role in human cancers. Consequently, GLI1 and its upstream positive regulator Smoothened (SMO) are important targets of anti-cancer therapy and several SMO-targeted small molecule inhibitors are being evaluated clinically. Emerging exciting evidence reveals a high level of complexity that lies within the GLI1-mediated pathway. For example, a recent study provided evidence linking the polymorphic GLI1 variants Q1100/E1100 to chronic inflammatory bowel diseases. Two recent reports uncovered the existence of two novel human GLI1 isoforms that differ structurally and functionally from the wild-type GLI1 identified over two decades ago. Interestingly, although both are products of alternative splicing, GLI1∆N and tGLI1 (truncated GLI1) isoforms are predominantly expressed in normal and malignant tissues, respectively. In addition to these important discoveries, gene expression profiling studies have identified a number of novel wild-type GLI1 and tGLI1 target genes, linking wild-type GLI1 to tumor progression and therapeutic resistance, and tGLI1 to tumor invasion and migration. In light of these new insights, this review will provide a comprehensive overview on GLI1 polymorphisms and the three members of the GLI1 family of proteins, and their impacts on human diseases, including, cancers.

Keywords: CD24; GLI1; GLI1∆N; Smoothened; Sonic Hedgehog pathway; cancer.; polymorphism; splice variants; tGLI1

References

  1. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13424-9 - PubMed
  2. Cancer Res. 1990 May 15;50(10):2987-90 - PubMed
  3. J Biol Chem. 2002 Sep 13;277(37):33632-40 - PubMed
  4. Oncogene. 2002 Apr 11;21(16):2476-83 - PubMed
  5. Lab Invest. 2005 Jul;85(7):921-31 - PubMed
  6. Nucleic Acids Res. 1990 May 11;18(9):2834 - PubMed
  7. Genes Chromosomes Cancer. 2000 Jun;28(2):220-6 - PubMed
  8. Anticancer Res. 2000 Jan-Feb;20(1A):329-36 - PubMed
  9. Science. 2009 Oct 23;326(5952):572-4 - PubMed
  10. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 - PubMed
  11. Science. 1987 Apr 3;236(4797):70-3 - PubMed
  12. Hum Mol Genet. 2005 Aug 1;14(15):2181-8 - PubMed
  13. J Biol Chem. 2001 Jan 12;276(2):1311-6 - PubMed
  14. Exp Dermatol. 2009 Sep;18(9):750-9 - PubMed
  15. Gene. 2004 Apr 14;330:101-14 - PubMed
  16. Cancer Res. 1998 May 1;58(9):1798-803 - PubMed
  17. Expert Rev Vaccines. 2008 Sep;7(7):977-85 - PubMed
  18. Mol Cancer Res. 2008 May;6(5):843-50 - PubMed
  19. Neuro Oncol. 2009 Apr;11(2):101 - PubMed
  20. Cancer Res. 1989 Oct 1;49(19):5407-13 - PubMed
  21. Cancer Res. 1999 Apr 15;59(8):1890-5 - PubMed
  22. Oncogene. 2006 Jan 26;25(4):609-21 - PubMed
  23. Curr Biol. 2007 Jan 23;17(2):165-72 - PubMed
  24. Mol Cell Biol. 1990 Feb;10(2):634-42 - PubMed
  25. Curr Mol Pharmacol. 2010 Jan;3(1):37-52 - PubMed
  26. Neuron. 1997 Jul;19(1):15-26 - PubMed
  27. Nature. 1988 Mar 24;332(6162):371-4 - PubMed
  28. Cancer Genet Cytogenet. 1987 Nov;29(1):165-70 - PubMed
  29. J Dent Res. 2008 Jun;87(6):575-9 - PubMed
  30. Nature. 1998 Jan 1;391(6662):90-2 - PubMed
  31. J Biol Chem. 1998 Feb 6;273(6):3496-501 - PubMed
  32. Genes Dev. 2006 Feb 1;20(3):276-81 - PubMed
  33. Cancer Res. 2002 Oct 15;62(20):5867-73 - PubMed
  34. Curr Oncol Rep. 2008 Mar;10(2):107-13 - PubMed
  35. Cell. 1994 Feb 25;76(4):761-75 - PubMed
  36. Nat Cell Biol. 1999 Sep;1(5):312-9 - PubMed
  37. Cancer Res. 1990 Apr 15;50(8):2347-50 - PubMed
  38. Biochem Biophys Res Commun. 2001 May 18;283(4):732-7 - PubMed
  39. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2880-4 - PubMed
  40. J Biol Chem. 2009 Aug 21;284(34):22888-97 - PubMed
  41. Development. 1997 Apr;124(7):1313-22 - PubMed
  42. J Virol. 1998 May;72(5):3958-64 - PubMed
  43. Nat Rev Cancer. 2003 Jul;3(7):489-501 - PubMed
  44. Cell Growth Differ. 1993 Dec;4(12):1065-70 - PubMed
  45. Growth Horm IGF Res. 2005 Jun;15(3):185-92 - PubMed
  46. Hum Genet. 1989 Apr;82(1):1-2 - PubMed
  47. Oncogene. 1999 Jan 21;18(3):833-6 - PubMed
  48. Eur J Cancer. 2006 Mar;42(4):437-45 - PubMed
  49. Nature. 2002 May 16;417(6886):299-304 - PubMed
  50. J Biol Chem. 2004 Jan 9;279(2):1197-205 - PubMed
  51. Am J Pathol. 2004 May;164(5):1645-53 - PubMed
  52. Oncogene. 2009 Apr 2;28(13):1639-51 - PubMed
  53. Cancer Res. 2005 Dec 1;65(23):10783-93 - PubMed
  54. J Hum Genet. 2009 Jul;54(7):403-8 - PubMed
  55. Cell. 1993 Dec 31;75(7):1417-30 - PubMed
  56. J Biol Chem. 2008 May 23;283(21):14345-54 - PubMed
  57. J Biol Chem. 2003 Feb 14;278(7):5116-22 - PubMed
  58. Cancer Genet Cytogenet. 1989 Jun;39(2):195-201 - PubMed
  59. Biochem Biophys Res Commun. 2004 Dec 24;325(4):1318-23 - PubMed
  60. Development. 2001 Dec;128(24):5201-12 - PubMed
  61. Curr Mol Med. 2009 Sep;9(7):873-86 - PubMed
  62. Cancer Res. 1995 Apr 15;55(8):1649-54 - PubMed
  63. Cancer Gene Ther. 2004 Aug;11(8):525-31 - PubMed
  64. Development. 1999 Jun;126(14):3089-100 - PubMed
  65. Nat Genet. 1997 Nov;17(3):269-71 - PubMed
  66. J Invest Dermatol. 2000 Aug;115(2):328-9 - PubMed
  67. Cancer Res. 2007 Oct 1;67(19):9066-76 - PubMed
  68. Cancer Res. 1997 Mar 1;57(5):842-5 - PubMed
  69. Anticancer Res. 2009 Oct;29(10):3759-68 - PubMed
  70. Hum Mutat. 2006 Mar;27(3):215-9 - PubMed
  71. Biochem Biophys Res Commun. 2008 Jan 4;365(1):35-41 - PubMed
  72. Int J Cancer. 2009 Jan 1;124(1):109-19 - PubMed
  73. Cancer Res. 2002 Aug 15;62(16):4773-80 - PubMed
  74. PLoS Med. 2008 Dec 9;5(12):e239 - PubMed
  75. Cancer Res. 2009 Sep 1;69(17):6790-8 - PubMed
  76. Nat Genet. 1997 Mar;15(3):266-8 - PubMed
  77. J Neurooncol. 2010 Jan;96(2):169-79 - PubMed
  78. J Biol Chem. 2002 Feb 15;277(7):5548-55 - PubMed

Publication Types

Grant support